Cart
sales@molnova.com
RH1
CAS No. 221635-42-3
RH1( —— )
Catalog No. M33479 CAS No. 221635-42-3
RH1 (NSC 697726) is a bioreductive anticancer compound that exhibits dose-dependent biphasic effects in vitro, inducing apoptosis at higher doses and senescence at lower doses.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 424 | In Stock |
|
| 10MG | 682 | In Stock |
|
| 25MG | 1378 | In Stock |
|
| 50MG | 1841 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameRH1
-
NoteResearch use only, not for human use.
-
Brief DescriptionRH1 (NSC 697726) is a bioreductive anticancer compound that exhibits dose-dependent biphasic effects in vitro, inducing apoptosis at higher doses and senescence at lower doses.
-
DescriptionRH1 (NSC 697726) is a bioreductive anticancer compound that exhibits dose-dependent biphasic effects in vitro, inducing apoptosis at higher doses and senescence at lower doses.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayApoptosis
-
TargetApoptosis
-
RecptorApoptosis
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number221635-42-3
-
Formula Weight234.25
-
Molecular FormulaC12H14N2O3
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=C1C(=C(C(=O)C(=C1C)N2CC2)CO)N3CC3
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
SACLAC
SACLAC is a cysteine asparaginase activation inhibitor with antitumor activity that decreases AML cell viability, inhibits AML cell proliferation, increases AML cell death, and induces apoptosis of AML cells, and is used in the study of acute myeloid leukemia and cancer.
-
CWI1-2 HCL
CWI1-2 HCL is an effective IGF2BP2 inhibitor, which can induce apoptosis and differentiation by binding IGF2BP2 and inhibiting its interaction with M6A-modified target transcription, and has therapeutic effects on leukemia.
-
PI3Kα-IN-9
PI3Kα-IN-9 is an orally available, selective and potent PI3Kα inhibitor with antiproliferative activity, inhibits PI3Kα, PI3Kγ, PI3Kδ, and PI3Kβ, induces apoptosis, and can be used in the study of cancer.
